<DOC>
	<DOCNO>NCT00495638</DOCNO>
	<brief_summary>The study look risk factor pulmonary hypertension ( high blood pressure lung ) child adolescent sickle cell anemia ( SCA ) examine role hypoxia ( oxygen shortage ) disease . In patient SCA , red blood cell become sickle-shaped tend form clump get stick blood vessel , block blood flow limb organ . Blocked blood vessel cause pain , serious infection , organ damage . Many patient SCA also develop pulmonary hypertension . Children adolescents SCA Chuvash polycythemia ( another blood disorder carry increase risk pulmonary hypertension ) may eligible study . Participants undergo follow procedure begin ( baseline ) end study : - History , physical examination blood test . - Echocardiography ( ultrasound study heart function ) . - Transcranial doppler ( brain ultrasound study measure brain blood flow ) . - Lung function test . - 6-minute walk ( measure distance cover 6 minute walk ) . In addition , patient follow telephone clinic visit every 6 month review medical history medication . A physical examination also do 12 month .</brief_summary>
	<brief_title>Pulmonary Hypertension , Hypoxia Sickle Cell Disease</brief_title>
	<detailed_description>The research design determine prevalence risk factor pulmonary hypertension ( PHT ) child adolescent sickle cell disease ( SCD ) , determine role hypoxic response pathogenesis . In regard , proliferative vascular response mediate ( ) hypoxia inducible factor ( HIF ) -regulated pathway ( ii ) nitric oxide ( NO ) -scavenging compare patient SCD patient Chuvash polycythemia ( CP ) , another hematological disorder characterize increase risk PHT . High throughput microarray genotyping technology employ identify candidate gene pholymorphisms involve pathologic response hypoxia SCD CP patient without PHT .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<criteria>INCLUSION CRITERIA A . For PAH child adolescent SCD : Inclusion criterion participant : 1 . The informed consent sign participant , parent legal guardian appropriate . 2 . Age 3 20 year . Inclusion criterion SCD patient : 1 . Diagnosis sickle cell disease ( electrophoretic HPLC documentation SS , SC , Sb thalassemia major sickling phenotype SD , SOArab SLepore require ) . 2 . At least three week elapse since hospitalization acute chest syndrome , pain crisis , infection complication SCD . 3 . Absence acute infection , pain crisis , acute complication SCD . ( Chronic SCD complication stutter priapism , stable chronic pain leg ulcer reason exclusion . ) Inclusion criterion control participant : 1 . Selfdescribed race African American . 2 . Absence diagnosis SCD define subsequent electrophoretic HPLC documentation . 3 . Absence acute infection , injury , surgery asthmatic episode . EXCLUSION CRITERIA : Exclusion criterion participant : 1 . Age le 3 year 21 year time enrollment . 2 . Presence acute infection , pain crisis , injury , surgery , asthmatic episode acute complication . Exclusion criterion SCD patient : 1 . Hemoglobin A phenotype , hemoglobin S trait hemoglobin C trait . 2 . Less three week elapse since hospitalization acute chest syndrome , pain crisis , infection complication SCD . Exclusion criterion control participant : 1 . Selfdescribed ethnicity African American . 2 . Diagnosis SCD electrophoretic HPLC documentation major sickling phenotype described . B. Angiogenic vasomotor response mediate HIFregulated pathway patient SCD CP without PAH . INCLUSION CRITERIA : Inclusion criterion participant : 1 . The informed consent sign participant , parent legal guardian appropriate . 2 . Age 3 year great . 3 . Absence acute infection , pain crisis , cerebral vascular accident , thrombosis acute complication . Inclusion criterion SCD CP patient PAH : 1 . Diagnosis SCD electrophoretic HPLC documentation SS , SC , Sbeta thalassemia major sickling phenotype SD , SOArab SLepore OR diagnosis CP evidence homozygosity mutation von HippelLindau gene position 598 cytosine thymidine . 2 . At least three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV 2.5 m/sec great . Inclusion criterion SCD CP patient without PAH : 1 . Diagnosis SCD electrophoretic HPLC documentation SS , SC , Sb thalassemia major sickling phenotype SD , SOArab SLepore OR diagnosis CP evidence homozygosity mutation von HippelLindau gene position 598 cytosine thymidine . 2 . At least three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV le 2.5 m/sec . 4 . Matched age ( plus minus 2 year ) , sex ethnicity specific patient SCD PAH CP PAH enrol study . Inclusion criterion control participant : 1 . Absence diagnosis SCD define subsequent electrophoretic documentation . 2 . Absence diagnosis CP subsequent documentation VHL 598 wildtype . 3 . At least three week elapse since hospitalization illness surgery . 4 . Matched age ( plus minus 2 year ) sex ethnicity specific patient SCD PAH CP PAH enrol study . 5 . Absence diagnosis PAH , anemia , polycythemia . EXCLUSION CRITERIA : Exclusion criterion participant : 1 . Age le 3 year . 2 . Presence condition associate secondary PAH SCD CP , collagen vascular disease , congenital heart disease , chronic lung disease . 3 . Presence acute infection , injury , surgery , asthmatic episode , pain crisis , cerebral vascular accident , thrombosis acute complication . Exclusion criterion SCD CP patient PAH : 1 . Hemoglobin AA phenotype , hemoglobin S trait , hemoglobin C trait mutation von HippelLindau gene position 598 cytosine thymidine heterozygosity VHL wildtype . 2 . Less three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV le 2.5 m/sec . Exclusion criterion SCD CP patient without PAH : 1 . Hemoglobin AA phenotype , hemoglobin S trait , hemoglobin C trait OR mutation von HippelLindau gene position 598 cytosine thymidine heterozygosity VHL wildtype . 2 . Less three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV great equal 2.5 m/sec . Exclusion criterion control participant : 1 . Diagnosis SCD electrophoretic HPLC evidence major sickling phenotype describe OR diagnosis CP mutation von HippelLindau gene position 598 cytosine thymidine homozygosity . 2 . ECHOdetermined TRV great equal 2.5 m/sec . C. High throughput microarray genotyping technology identify candidate gene polymorphism involve pathologic response hypoxia SCD CP patient PAH . INCLUSION CRITERIA : Inclusion criterion participant : 1 . The informed consent sign participant , parent legal guardian appropriate . 2 . Age 3 year great . 3 . Absence acute infection , pain crisis , cerebral vascular accident , thrombosis acute complication . Inclusion criterion SCD CP patient PAH : 1 . Diagnosis SCD electrophoretic HPLC documentation SS , SC , Sb thalassemia major sickling phenotype SD , SOArab SLepore OR diagnosis CP evidence homozygosity mutation von HippelLindau gene position 598 cytosine thymidine . 2 . At least three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV 2.5 m/sec great . Inclusion criterion SCD CP patient without PAH : 1 . Diagnosis SCD electrophoretic HPLC documentation SS , SC , Sb thalassemia major sickling phenotype SD , SOArab SLepore OR diagnosis CP evidence homozygosity mutation von HippelLindau gene position 598 cytosine thymidine . 2 . At least three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 3 . ECHOdetermined TRV le 2.5 m/sec 4 . Matched age ( plus minus 2 year ) , sex ethnicity specific patient SCD PAH CP PAH enrol study . Inclusion criterion screen population prevalence polymorphism : 1 . Absence diagnosis SCD , CP PAH . 2 . Selfdescribed AfricanAmerican Chuvash ethnicity . EXCLUSION CRITERIA : Exclusion criterion participant : 1 . Age le 3 year . 2 . Presence acute infection , injury , surgery , asthmatic episode , pain crisis , cerebral vascular accident , thrombosis acute complication . Exclusion criterion SCD CP patient PAH : 1 . Hemoglobin AA phenotype , hemoglobin S trait , hemoglobin C trait OR mutation von HippelLindau gene position 598 cytosine thymidine heterozygosity VHL wildtype . 2 . Presence condition associate secondary PAH SCD CP , collagen vascular disease , congenital heart disease , chronic lung disease . 3 . Less three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 4 . ECHOdetermined TRV le 2.5 m/sec . Exclusion criterion SCD CP patient without PAH : 1 . Hemoglobin AA phenotype , hemoglobin S trait , hemoglobin C trait OR mutation von HippelLindau gene position 598 cytosine thymidine heterozygosity VHL wildtype . 2 . Presence condition associate secondary PAH SCD CP , collagen vascular disease , congenital heart disease , chronic lung disease . 3 . Less three week elapse since hospitalization SCD ( acute chest syndrome , pain crisis , infection complication ) CP ( cerebral vascular accident , thrombotic event complication ) . 4 . ECHOdetermined TRV great equal 2.5 m/sec . Exclusion criterion screen population prevalence polymorphisms 1 . Diagnosis SCD , CP PAH . 2 . Selfdescribed ethnicity AfricanAmerican Chuvash .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2, 2014</verification_date>
	<keyword>6-Minute Walk</keyword>
	<keyword>Chuvash Polycythemia</keyword>
	<keyword>Echocardiogram</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Pulmonary Function Tests</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>SCD</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>